Meta-analysis updated with DIAGNODE-2 results provides further support for a precision medicine approach using Diamyd[®]
The large scale meta-analysis, previously published in August 2020, based on data from Phase III and Phase II trials in Europe and in the United States with the type 1 diabetes vaccine Diamyd[®] (GAD/alum), has been updated with data from the recenly announced (Sep 2020) European Phase IIb trial DIAGNODE-2. This meta-analysis comprises data from 627 individual patients and provides further support for a positive and statistically significant dose-dependent treatment response on the preservation of endogenous insulin production in individuals with type 1 diabetes that carry the HLA DR3-DQ2